A meta-analysis of 16 studies in JMIR Mental Health finds wearable AI models detect existing depression with up to 96% accuracy, but the same technology performs far worse at predicting future depressive episodes, raising questions about real-world readiness.
GE HealthCare and Mass General Brigham announced a research collaboration on September 23, 2026 to explore generative AI that helps radiation oncology teams navigate scattered treatment records. The project builds on earlier MGH software that GE says cut treatment start times from 30 days to eight at one hospital.
Rome's Sant'Andrea University Hospital routed nearly 5,700 emergency ECGs through Powerful Medical's Queen of Hearts AI over six months, catching STEMI-equivalent heart attacks that standard criteria often miss and alerting cardiologists in under 17 seconds. The case study, released October 7, 2026, comes as the AI also gains FDA authorization and expands into prehospital ambulance care.
UpDoc has announced FDA clearance for software that gives type 2 diabetes patients insulin dosing instructions through a conversational interface, a device the FDA record shows was cleared in December 2025 as a bounded, physician-configured insulin calculator rather than an autonomous AI doctor.
Medidata's second annual survey of pharmaceutical trial sponsors found experienced AI adopters report faster timelines and fewer protocol deviations, but most of the industry says AI has yet to meet expectations, with gains so far concentrated in routine administrative workflows.
A nationwide German study of nearly 500,000 women found AI-assisted mammogram reading increased breast cancer detection by about 17.6% without raising false positives, offering some of the strongest real-world evidence yet for AI's role in cancer screening.
Bloomberg reports Alphabet's AI drug discovery unit is in early talks to raise at double its prior valuation, even as Demis Hassabis pushes back his timeline for the company's first human clinical trial to the end of 2026.
Tempus AI has expanded its collaboration with Merck and Moderna to help commercialize intismeran autogene, a personalized mRNA cancer vaccine built from each patient's tumor sequencing, as Tempus moves to acquire Personalis for its genomic profiling technology.
Pennsylvania has sued Character.AI, alleging its chatbots falsely posed as licensed mental health professionals, including one bot impersonating a psychiatrist that provided a fabricated state license number.
A federal judge in Minnesota has ordered UnitedHealth to produce internal documents about its nH Predict algorithm, used to deny rehabilitation care to Medicare Advantage patients, after a lawsuit alleged the tool had a 90 percent error rate on appeal.